Xenon Pharmaceuticals Inc (XENE) has a current Price-to-Book (P/B) ratio of 6.13. Compared to its 3-year average P/B ratio of 3.87, the current P/B ratio is approximately 58.31% higher. Relative to its 5-year average P/B ratio of 3.61, the current P/B ratio is about 69.81% higher. Xenon Pharmaceuticals Inc (XENE) has a Forward Free Cash Flow (FCF) yield of approximately -7.37%. Compared to its 3-year average FCF yield of -5.95%, the current FCF yield is approximately 23.84% lower. Relative to its 5-year average FCF yield of -5.62%, the current FCF yield is about 31.20% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XENE competitors is 768.92, providing a benchmark for relative valuation. Xenon Pharmaceuticals Inc Corp (XENE.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XENE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XENE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XENE currently overvalued or undervalued?

What is Xenon Pharmaceuticals Inc (XENE) fair value?

XENE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Xenon Pharmaceuticals Inc (XENE) is between to according to relative valuation method.

How does XENE's valuation metrics compare to the industry average?

The average P/S ratio for XENE's competitors is 768.92, providing a benchmark for relative valuation. Xenon Pharmaceuticals Inc Corp (XENE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Xenon Pharmaceuticals Inc (XENE) as of Mar 02 2026?

As of Mar 02 2026, Xenon Pharmaceuticals Inc (XENE) has a P/B ratio of 6.13. This indicates that the market values XENE at 6.13 times its book value.

What is the current FCF Yield for Xenon Pharmaceuticals Inc (XENE) as of Mar 02 2026?

As of Mar 02 2026, Xenon Pharmaceuticals Inc (XENE) has a FCF Yield of -7.37%. This means that for every dollar of Xenon Pharmaceuticals Inc's market capitalization, the company generates -7.37 cents in free cash flow.

What is the current Forward P/E ratio for Xenon Pharmaceuticals Inc (XENE) as of Mar 02 2026?

As of Mar 02 2026, Xenon Pharmaceuticals Inc (XENE) has a Forward P/E ratio of -9.42. This means the market is willing to pay $-9.42 for every dollar of Xenon Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Xenon Pharmaceuticals Inc (XENE) as of Mar 02 2026?

As of Mar 02 2026, Xenon Pharmaceuticals Inc (XENE) has a Forward P/S ratio of 0.00. This means the market is valuing XENE at $0.00 for every dollar of expected revenue over the next 12 months.

XENE Valuation